Drug Profile
SITS
Latest Information Update: 01 Sep 1998
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Anti-ischaemics; Stilbenes
- Mechanism of Action Chloride channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 01 Sep 1998 No-Development-Reported for Arrhythmias (Unknown route)
- 01 Sep 1998 No-Development-Reported for Immunological disorders in Canada (Unknown route)
- 13 Dec 1996 SITS is being developed for use in Immunological Disorders